AstraZeneca Says Enhertu Improved Survival in Trial Breast-Cancer Patients
August 09 2021 - 2:43AM
Dow Jones News
By Jaime Llinares Taboada
AstraZeneca PLC said Monday that its Enhertu cancer treatment
achieved positive results at its first phase III head-to-head
trial.
The pharmaceutical company said the trial compared Enhertu with
trastuzumab emtansine on patients with HER2-positive breast cancer.
HER2 protein overexpression is often associated with aggressive
disease and a poor prognosis in breast cancer.
An independent committee concluded that the trial met the
primary endpoint of progression-free survival, showing improvements
for patients with HER2-positive breast cancer.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
August 09, 2021 02:35 ET (06:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
